A Phase 3 biosimilar study (NCT06587451) comparing JPB898, a proposed biosimilar to Nivolumab (Opdivo), in participants with advanced melanoma reached primary completion on 2026-01-23. The study aimed to demonstrate similar pharmacokinetics, efficacy, safety, and immunogenicity between JPB898 and reference Nivolumab.
Background
Nivolumab, marketed as Opdivo, is an established immunotherapy. The study investigated JPB898 as a proposed biosimilar to Nivolumab, specifically in combination with Yervoy-EU during the induction phase, for the treatment of advanced melanoma.
Trial design
The Phase 3 study (NCT06587451) was designed as an integrated pharmacokinetics (PK)/efficacy, safety, and immunogenicity study. It enrolled 52 participants with advanced (unresectable Stage III or metastatic Stage IV) melanoma. Interventions included JPB898 (induction and maintenance), Opdivo-EU (induction), Opdivo-US (induction), and Yervoy-EU (induction). The primary objective was to demonstrate similarity of JPB898 to Opdivo-EU and Opdivo-US.
What this means
The primary completion of this Phase 3 study indicates that data collection for its primary endpoints has concluded. While the study's overall status is listed as TERMINATED, the completion of primary data collection is a significant milestone for the development of JPB898 as a potential biosimilar to Nivolumab. Results from this study will be crucial for evaluating the comparability of JPB898 to the reference product.
Source
The information regarding the primary completion of this trial was obtained from the ClinicalTrials.gov study record for NCT06587451, titled "Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®". The primary completion date was reported as 2026-01-23 on clinicaltrials.gov.